Lessons for inflammatory bowel disease from rheumatology

Digestive and Liver Disease

Volumn 38, Issue 3, 2006, Pages 157-162

  Rhodes, J M ^a   Collins, P ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; ETANERCEPT; HLA ANTIGEN CLASS 2; HLA B51 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; MESALAZINE; NEUTROPHIL CYTOPLASMIC ANTIBODY; SALAZOSULFAPYRIDINE; SULFAPYRIDINE;

ANTIGEN BINDING; APOPTOSIS; BACTERIUM; BEHCET DISEASE; CANCER RISK; CARCINOGENESIS; CHRONIC INFLAMMATION; COLITIS; CROHN DISEASE; DISEASE ASSOCIATION; DNA DAMAGE; DRUG ABSORPTION; DRUG ACETYLATION; DRUG MECHANISM; ENTERITIS; ENVIRONMENTAL FACTOR; EVIDENCE BASED MEDICINE; GASTROENTEROLOGY; GENETICS; HUMAN; INCIDENCE; JAPAN; MEDICAL LITERATURE; MEDICAL RESEARCH; NONHUMAN; PATHOGENESIS; PROTEIN FUNCTION; PROTEIN INDUCTION; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; SHORT SURVEY; SMOKING; TURKEY (REPUBLIC); ULCERATIVE COLITIS; VASCULITIS; REVIEW;

ARTHRITIS, RHEUMATOID; COLITIS, ULCERATIVE; CROHN DISEASE; HUMANS;

EID: 33746094346     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2005.09.020     Document Type: Short Survey

References (56)

1. Svendsen A.J., Holm N.V., Kyvik K., Petersen P.H., and Junker P. Relative importance of genetic effects in rheumatoid arthritis: historical cohort study of Danish nationwide twin population. Br Med J 324 (2002) 264-266
2. Halfvarson J., Bodin L., Tysk C., Lindberg E., and Jarnerot G. Inflammatory bowel disease in a Swedish twin cohort: a long-term follow-up of concordance and clinical characteristics. Gastroenterology 124 (2003) 1767-1773
3. MacGregor A.J., Snieder H., Rigby A.S., Koskenvuo M., Kaprio J., Aho K., et al. Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum 43 (2000) 30-37
4. Russell R.K., Nimmo E.R., and Satsangi J. Molecular genetics of Crohn's disease. Curr Opin Genet Dev 14 (2004) 264-270
5. Buckner J.H., and Nepom G.T. Genetics of rheumatoid arthritis: is there a scientific explanation for the human leukocyte antigen association?. Curr Opin Rheumatol 14 (2002) 254-259
6. van der Helm-van Mil A.H.M., Wesoly J.Z., and Huizinga T.W.J. Understanding the genetic contribution to rheumatoid arthritis. Curr Opin Rheumatol 17 (2005) 299-304
7. Fernandez L., Nunez C., Mendoza J.L., Urcelay E., Fernandez-Arquero M., Taxonera C., et al. A recombined haplotype in the major histocompatibility region contains a cluster of genes conferring high susceptibility to ulcerative colitis in the Spanish population. Inflamm Bowel Dis 11 (2005) 785-791
8. Probert C.S., Jayanthi V., Hughes A.O., Thompson J.R., Wicks A.C., and Mayberry J.F. Prevalence and family risk of ulcerative colitis and Crohn's disease: an epidemiological study among Europeans and south Asians in Leicestershire. Gut 34 (1993) 1547-1551
9. Gibert M., and Sanchez-Mazas A. Geographic patterns of functional categories of HLA-DRB1 alleles: a new approach to analyse associations between HLA-DRB1 and disease. Eur J Immunogenet 30 (2003) 361-374
10. Alamanos Y., and Drosos A.A. Epidemiology of adult rheumatoid arthritis. Autoimmun Rev 4 (2005) 130-136
11. Garcia Rodriguez L.A., Gonzalez-Perez A., Johansson S., and Wallander M.A. Risk factors for inflammatory bowel disease in the general population. Aliment Pharmacol Ther 22 (2005) 309-315
12. Reckner Olsson A., Skogh T., and Wingren G. Comorbidity and lifestyle, reproductive factors, and environmental exposures associated with rheumatoid arthritis. Ann Rheum Dis 60 (2001) 934-939 Erratum in: Ann Rheum Dis 2001;60:1161
13. Wakefield A.J., Sawyerr A.M., Hudson M., Dhillon A.P., and Pounder R.E. Smoking, the oral contraceptive pill, and Crohn's disease. Dig Dis Sci 36 (1991) 1147-1150
14. Kotani N., Kushikata T., Hashimoto H., Sessler D.I., Muraoka M., and Matsuki A. Recovery of intraoperative microbicidal and inflammatory functions of alveolar immune cells after a tobacco smoke-free period. Anesthesiology 94 (2001) 999-1006
15. Logan R.F. Inflammatory bowel disease incidence: up, down or unchanged?. Gut 42 (1998) 309-311
16. Binder V. Epidemiology of IBD during the twentieth century: an integrated view. Best Pract Res Clin Gastroenterol 18 (2004) 463-479
17. Shivananda S., Lennard-Jones J., Logan R., Fear N., Price A., Carpenter L., et al. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut 39 (1996) 690-697
18. Cleland L.G., James M.J., and Proudman S.M. The role of fish oils in the treatment of rheumatoid arthritis. Drugs 63 (2003) 845-853
19. Seidner D.L., Lashner B.A., Brzezinski A., Banks P.L., Goldblum J., Fiocchi C., et al. An oral supplement enriched with fish oil, soluble fiber, and antioxidants for corticosteroid sparing in ulcerative colitis: a randomized, controlled trial. Clin Gastroenterol Hepatol 3 (2005) 358-369
20. Lorenz-Meyer H., Bauer P., Nicolay C., Schulz B., Purrmann J., Fleig W.E., et al. Omega-3 fatty acids and low carbohydrate diet for maintenance of remission in Crohn's disease. A randomized controlled multicenter trial. Study group members (German Crohn's Disease Study Group). Scand J Gastroenterol 31 (1996) 778-785
21. Belluzzi A., Brignola C., Campieri M., Pera A., Boschi S., and Miglioli M. Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. N Engl J Med 334 (1996) 1557-1560
22. Padyukov L., Silva C., Stolt P., Alfredsson L., and Klareskog L. A gene-environment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis. Arthritis Rheum 50 (2004) 3085-3092
23. Takeno M., and Ishigatsubo Y. Behcet's disease and inflammatory bowel disease. Intern Med 43 (2004) 172-173
24. Yurdakul S., Tuzuner N., Yurdakul I., Hamuryudan V., and Yazici H. Gastrointestinal involvement in Behcet's syndrome: a controlled study. Ann Rheum Dis 55 (1996) 208-210
25. Pirim I., Atasoy M., Ikbal M., Erdem T., and Aliagaoglu C. HLA class I and class II genotyping in patients with Behcet's disease: a regional study of eastern part of Turkey. Tissue Antigens 64 (2004) 293-297
26. Mizuki N., Ota M., Katsuyama Y., Yabuki K., Ando H., Shiina T., et al. HLA-B*51 allele analysis by the PCR-SBT method and a strong association of HLA-B*5101 with Japanese patients with Behcet's disease. Tissue Antigens 58 (2001) 181-184
27. De Vos M. Review article: joint involvement in inflammatory bowel disease. Aliment Pharmacol Ther 20 Suppl. 4 (2004) 36-42
28. Klebl F.H., Bataille F., Huy C., Hofstadter F., Scholmerich J., and Rogler G. Association of antibodies to exocrine pancreas with subtypes of Crohn's disease. Eur J Gastroenterol Hepatol 17 (2005) 73-77
29. Kovvali G., and Das K.M. Molecular mimicry may contribute to pathogenesis of ulcerative colitis. FEBS Lett 579 (2005) 2261-2266
30. Cohavy O., Bruckner D., Gordon L.K., Misra R., Wei B., Eggena M.E., et al. Colonic bacteria express an ulcerative colitis pANCA-related protein epitope. Infect Immun 68 (2000) 1542-1548
31. Israeli E., Grotto I., Gilburd B., Balicer R.D., Goldin E., Wiik A., et al. Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. Gut 54 (2005) 1232-1236
32. Xiao H., Heeringa P., Hu P., Liu Z., Zhao M., Aratani Y., et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 110 (2002) 955-963
33. Xiao H., Heeringa P., Liu Z., Huugen D., Hu P., Maeda N., et al. The role of neutrophils in the induction of glomerulonephritis by anti-myeloperoxidase antibodies. Am J Pathol 167 (2005) 39-45
34. http://www.decisionresources.com accessed on 7 Sept 2005.
35. Bird H.A. Sulphasalazine, sulphapyridine or 5-aminosalicylic acid-which is the active moiety in rheumatoid arthritis?. Br J Rheumatol 34 Suppl. 2 (1995) 16-19
36. Azad Khan A.K., Piris J., and Truelove S.C. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 2 (1977) 892-895
37. Rousseaux C., Lefebvre B., Dubuquoy L., Lefebvre P., Romano O., Auwerx J., et al. Intestinal anti-inflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J Exp Med 201 (2005) 1205-1215
38. Allgayer H., Ahnfelt N.O., Kruis W., Klotz U., Frank-Holmberg K., Soderberg H.N., et al. Colonic N-acetylation of 5-aminosalicylic acid in inflammatory bowel disease. Gastroenterology 97 (1989) 38-41
39. Volin M.V., Harlow L.A., Woods J.M., Campbell P.L., Amin M.A., Tokuhira M., et al. Treatment with sulfasalazine or sulfapyridine, but not 5-aminosalicyclic acid, inhibits basic fibroblast growth factor-induced endothelial cell chemotaxis. Arthritis Rheum 42 (1999) 1927-1935
40. Wahl C., Liptay S., Adler G., and Schmid R.M. Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest 101 (1998) 1163-1174
41. Targan S.R., Hanauer S.B., van Deventer S.J., Mayer L., Present D.H., Braakman T., et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's disease cA2 study group. N Engl J Med 337 (1997 Oct 9) 1029-1035
42. Present D.H., Rutgeerts P., Targan S., Hanauer S.B., Mayer L., van Hogezand R.A., et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340 (1999) 1398-1405
43. Hanauer S.B., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., et al., ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359 (2002) 1541-1549
44. Rutgeerts P., Feagan B.G., Olson A., et al. A randomized placebo-controlled trial of infliximab therapy for ulcerative colitis: ACT 1 trial. Gastroenterology 128 4; Suppl 2 (2005) A105 [abstract 689]
45. Sandborn W.J., Rachmilewitz D.R., Hanauer S.B., et al. Infliximab induction and maintenance therapy for ulcerative colitis: the ACT 2 trial. Gastroenterology 128 4; Suppl 2 (2005) A104-A105 [abstract 688]
46. Jarnerot G., Hertervig E., Friis-Liby I., Blomquist L., Karlen P., Granno C., et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 128 (2005) 1805-1811
47. Maini R.N., Breedveld F.C., Kalden J.R., Smolen J.S., Davis D., Macfarlane J.D., et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor αmonoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41 (1998) 1552-1563
48. Maini R., St. Clair E.W., Breedveld F., Furst D., Kalden J., Weisman M., et al. Infliximab (chimeric anti-tumor necrosis factor αmonoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. Lancet 354 (1999) 1932-1939
49. Moreland L.W., Schiff M.H., Baumgartner S.W., et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 130 (1999) 478-486
50. Sandborn W.J., Hanauer S.B., Katz S., Safdi M., Wolf D.G., Baerg R.D., et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 121 (2001) 1088-1094
51. Van den Brande J.M., Braat H., van den Brink G.R., Versteeg H.H., Bauer C.A., Hoedemaeker I., et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 124 (2003) 1774-1785
52. Sawada K., Muto T., Shimoyama T., Satomi M., Sawada T., Nagawa H., et al. Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis column. Curr Pharm Des 9 (2003) 307-321
53. Ohara M., Saniabadi A.R., Kokuma S., Hirata I., Adachi M., Agishi T., et al. Granulocytapheresis in the treatment of patients with rheumatoid arthritis. Artif Organs 21 (1997) 989-994
54. Kashiwagi N., Hirata I., and Kasukawa R. A role for granulocyte and monocyte apheresis in the treatment of rheumatoid arthritis. Ther Apher 2 (1998) 134-141
55. Greten F.R., Eckmann L., Greten T.F., Park J.M., Li Z.W., Egan L.J., et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118 (2004) 285-296
56. Rhodes J.M., and Campbell B.J. Inflammation and colorectal cancer: inflammatory bowel disease-associated cancer and sporadic cancer compared. Trends Mol Med 8 (2002) 10-16